NCT02889848View on ClinicalTrials.gov

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

October 5, 2018

Study Completion Date

November 15, 2018

Conditions
Fibroids, UterineLeiomyoma
Interventions
OTHER

Saline

Saline injection

DRUG

EN3835

Comparison of maximum marketed dose and multiple doses EN3835

Trial Locations (1)

21205

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Advance Biofactures Corporation

INDUSTRY

NCT02889848 - Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) | Biotech Hunter | Biotech Hunter